Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma

Purpose Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC). Methods The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-N...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2018-06, Vol.169 (2), p.295-304
Main Authors: Hamy, Anne-Sophie, Lam, Giang-Thanh, Laas, Enora, Darrigues, Lauren, Balezeau, Thomas, Guerin, Julien, Livartowski, Alain, Sadacca, Benjamin, Pierga, Jean-Yves, Vincent-Salomon, Anne, Coussy, Florence, Becette, Veronique, Bonsang-Kitzis, Hélène, Rouzier, Roman, Feron, Jean-Guillaume, Benchimol, Gabriel, Laé, Marick, Reyal, Fabien
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Adult
Breast cancer
Breast carcinoma
Breast Neoplasms - drug therapy
Breast Neoplasms - epidemiology
Breast Neoplasms - pathology
Cancer metastasis
Cancer research
Chemotherapy
Clinical Study
Clinical trials
Disease-Free Survival
ErbB-2 protein
Female
Humans
Lymph Nodes - drug effects
Lymph Nodes - pathology
Lymphatic Metastasis
Medical prognosis
Medicine
Medicine & Public Health
Metastases
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness - pathology
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Oncology
Prognosis
Survival
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - epidemiology
Triple Negative Breast Neoplasms - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC). Methods The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-NAC prognostic scores (ypAJCC, RCB, CPS, CPS + EG and Neo-Bioscore) were evaluated and compared with or without the addition of LVI. Results Out of 1033 tumors, LVI was present on surgical specimens in 29.2% and absent in 70.8% of the cases. Post-NAC LVI was associated with impaired disease-free survival (DFS) (HR 2.54; 95% CI 1.96–3.31; P  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-017-4610-0